 The FDA has signed off Cidara Therapeutics Incs NASDAQ: CDTX Investigational New Drug IND application for its lead flu drug-Fc conjugate DFC, CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. 